TORONTO, Aug 11 (Reuters) - Toronto Stock Exchange’s main index opened lower on Monday, weighed down by materials stocks while news relating to Cardiome Pharma Corp’s (COM.TO) Kynapid heart treatment was also a drag on sentiment.
Shortly after the open, the S&P/TSX composite index .GSPTSE was down 60.67 points, or 0.5 percent, at 13,281.07, with six of its 10 main groups lower.
The resource-laden materials sector sank 2.9 percent, in line with a slump in the price of bullion. Yamana Gold (YRI.TO) slipped 28 Canadian cents, or 2.5 percent, to C$10.81.
The healthcare group slid 9 percent. Shares of Cardiome slid 27 percent to C$9.37 after it and Astellas Pharma US, Inc. (4503.T) announced the receipt of an FDA approvable letter for Kynapid.
Cardiome said the FDA requested additional information, including a safety update from ongoing or completed studies of vernakalant, which is used in the treatment of atrial fibrillation or abnormal heart rhythm. ($1=$1.07 Canadian) (Reporting by Jennifer Kwan; Editing by Bernadette Baum)